<DOC>
	<DOCNO>NCT00593099</DOCNO>
	<brief_summary>The purpose pilot study determine safety potential efficacy sustained-release bupropion ( Zyban® ) treatment nicotine dependence patient bipolar affective illness . It hypothesize bupropion produce significant enhancement smoking abstinence compare placebo safe use patient .</brief_summary>
	<brief_title>A Preliminary Study Sustained-Release Bupropion Smoking Cessation Bipolar Affective Disorder</brief_title>
	<detailed_description>The purpose pilot study determine safety potential efficacy sustained-release bupropion ( Zyban® ) treatment nicotine dependence patient bipolar affective illness . propose conduct preliminary study safety efficacy bupropion SR ( flexible dose 300 mg/day ) comparison placebo medication-maintained stabilized outpatient bipolar I II disorder currently depress despite mood-stabilizing medication also nicotine-dependent cigarette smoker , motivate quit smoking . Subjects n=32 subject 18 65 year age meet DSM-IV criterion bipolar disorder ( either Type I II ) , nicotine dependence , smoke least 15 cigarette per day , FTND score baseline &gt; 5 , expire breath CO &gt; 10 , plasma cotinine &gt; 150 ng/ml , motivate quit smoking within thirty day initial intake . Subjects must stable dose mood stabilizer ( e.g . lithium , valproate , carbamezepine , topiramate , gabapentin atypical antipsychotic ) , complete remission active manic hypomanic psychotic symptom judge psychiatric evaluation . Subjects recruit outpatient department Connecticut Mental Health Center ( CMHC ) satellite clinic . Study medication give 9 week duration , begin 1 week prior `` quit date '' . Bupropion [ intermediate-release ( IR ) formulation ] begin 75 mg po qd x 3days , increase 150 mg [ bupropion SR formulation ] qd x 4 day , increase final dose 150 mg po bid ( 300 mg/day ) Day 15 ( target quit date ; TQD ) tolerate , dose continue additional eight ( 8 ) week 150 mg po bid . We allow flexible dose 150 mg/day allow adjustment need bipolar subject tolerate full dose Zyban 300 mg/day . Zyban discontinue end Week 10 . Primary outcome measure endpoint ( 7-day ) smoke abstinence adverse event .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Mood Disorders</mesh_term>
	<mesh_term>Genetic Diseases , X-Linked</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>1 . SCID DSMIV diagnose bipolar I bipolar II disorder , nicotine dependence . 2 . Young Mania Rating Scale Total Score &lt; 12 study entry . 3 . BPRS Total Score &lt; 20 study entry 4 . HAMD 17Item Score &gt; 12 &lt; 25 study entry . NB : We set upper limit allowable HAMD 17item score since high score would typically trigger initiation antidepressant trial , study involves placebocontrolled augmentation exist medication therapy bupropion . 5 . Fagerstrom Test Nicotine Dependence ( FTND ) score 4 . 6 . Smoking least 15 cigarette per day , expire breath CO level &gt; 10 ppm plasma cotinine level &gt; 150 ng/ml baseline . 7 . Be stable dose mood stabilizer least 1 month ( e.g . lithium , valproate , carbamazepine , atypical antipsychotic ) judge study psychiatrist ( T. George , M.D . H. Blumberg , M.D . ) , judge welltrained trained psychiatric clinician ( e.g . J. Vessicchio , M.S.W . K. Sacco , Psy.D . ) remission active manic , hypomanic , major depression psychotic symptom base clinical interview SCIDIV . 8 . Be able provide inform consent participate study judge clinical evaluation , score least 80 % postconsent `` test '' . 1 . Meet criteria current abuse dependence alcohol illicit substance within past 3 month study enrollment . 2 . Current evidence SCIDIV clinical evaluation suicidality , homocidality psychosis . 3 . Meet DSMIV criterion current major depression time baseline evaluation . 4 . A history hypersensitivity know adverse reaction ( e.g . hyperstimulation , severe agitation ) bupropion . 5 . Any serious documented medical disorder might contraindicate bupropion ( i.e . anorexia bulimia nervosa , history seizure disorder , history major head injury loss consciousness period great five minute ) , result psychiatric/medical screen suggest reason concern trial bupropion ( e.g. , history severe cardiac , renal hepatic disease , diabetes mellitus thyroid abnormality opinion study internist Dr. Lynn Sullivan would preclude participation study ) . 6 . Evidence clinically significant EKG abnormality judge study internist , Lynn E. Sullivan , M.D . ( Department Internal Medicine , YUSM ) , designate . 7 . Prescription monoamine oxidase inhibitor Wellbutrin® formulation bupropion . 8 . The presence manic , mixed manic hypomanic symptom past one ( 1 ) month prior study enrollment . 9 . A lifetime history antidepressantinduced mania hypomania . 10 . A history suicidal ideation take antidepressant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Nicotine Dependence</keyword>
	<keyword>Smoking Cessation</keyword>
	<keyword>Bupropion , sustained-release</keyword>
</DOC>